ENTITY

Cloudbreak Pharma (2592 HK)

4
Analysis
Health Care • United States
Cloudbreak Pharma is a clinical-stage ophthalmology biotechnology company dedicated to developing novel and differentiated treatments for eye diseases, leveraging its proprietary Multi-Kinase Inhibitor (MKI) platform. Its pipeline includes lead candidates such as CBT-001 for pterygium and CBT-004 for pinguecula, both in late-stage clinical trials. The company was founded in 2015 and is headquartered in Irvine, California, USA, with operations also in Mainland China and Hong Kong.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x